subscribeSubscribe
Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab

Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab
GLOBENEWSWIRE
04 Apr 2023
Share Share
Gamifant (emapalumab) recommended for approval in China for HLH

Gamifant (emapalumab) recommended for approval in China for HLH
PRNEWSWIRE
25 Feb 2022
Share Share
Emapalumab submission in China for primary HLH

Emapalumab submission in China for primary HLH
PRNEWSWIRE
10 Dec 2020
Share Share
The CHMP has adopted a negative opinion for emapalumab in Europe

The CHMP has adopted a negative opinion for emapalumab in Europe
PRESS RELEASE
13 Nov 2020
Share Share
Sobi bets $250M cash, about $1B in milestones for rights to a C3 therapy

Sobi bets $250M cash, about $1B in milestones for rights to a C3 therapy
N.DeFeudis ENDPTS
28 Oct 2020
Share Share
Meeting highlights from Committee for Medicinal Products for Human Use (CHMP)

Meeting highlights from Committee for Medicinal Products for Human Use (CHMP)
EMA
18 Sep 2020
Share Share
Sobi to refile Gamifant following CHMP rejection

Sobi to refile Gamifant following CHMP rejection
Selina McKee PHARMATIMES
27 Jul 2020
Share Share
EMA: Thumbs up for 11, down for 2 new medicines

EMA: Thumbs up for 11, down for 2 new medicines
Kari Oakes RAPS
25 Jul 2020
Share Share
Sobi`s high-priority rare disease drug runs into a wall at EMA

Sobi`s high-priority rare disease drug runs into a wall at EMA
Amber Tong ENDPTS
24 Jul 2020
Share Share
Results From Pivotal Ph2/3 Study of Emapalumab in Patients With Primary HLH

Results From Pivotal Ph2/3 Study of Emapalumab in Patients With Primary HLH
PRNEWSWIRE
07 May 2020
Share Share